Eli Lilly launches its Alzheimer’s disease drug donanemab in India, according to reports from Seeking Alpha and The Economic Times. The sources state that the treatment is now available in the Indian market as part of Eli Lilly’s efforts to expand access to therapies for Alzheimer’s. Donanemab is an anti-amyloid therapy designed for patients with Alzheimer’s disease, and the launch reflects the company’s move to bring the drug to additional geographies following broader commercialization in other markets.
Both outlets describe the Indian rollout as a new commercial availability event, though they provide limited detail in the excerpts provided about pricing, reimbursement coverage, or specific hospital/physician access pathways. The reports also do not indicate any changes to the drug’s indication or manufacturing specifics for India within the text supplied. Overall, the agreement across sources centers on the timing and location of the launch—India—and the introduction of donanemab as Eli Lilly’s Alzheimer’s therapy in the country.
